论文部分内容阅读
一个特别值得注意的尿路感染治疗新进展是抑制变形杆菌脲酶活性的药物。最近Musher等应用乙酰氧肟酸(acetohydroxamic acid),Aronson等应用硫脲和羟基脲(这两种实验性药物应用于人类可能毒性太大)进行研究。表明很有希望。由于变形杆菌的毒力似大于其他肠道菌,因此变形杆菌感染具有特殊重要性。例如,Fairley等报导的关于膀胱与肾脏定位的研究表明,实际上所有变形杆菌尿症患者同时都有上尿路感染的证据。Musher等和Aronson等对动物模型的研究表明,当阻碍氨生成时,变形杆菌感染的毒力大为减弱。在这种情况下,变形杆菌的表现酷似其他肠道菌。上述研究指出脲酶作为变形杆菌毒力因子的潜在重要性。其确切机理迄未明了。变形杆菌感染的另一个问题是大多数抗
A particularly noteworthy new advance in the treatment of urinary tract infections is the drug that inhibits the activity of Proteus urease. Recently, Musher et al. Used acetohydroxamic acid and Aronson et al. To study the use of thiourea and hydroxyurea, both of which are potentially toxic to humans. Shows great hope. Proteus infection is of special importance because Proteus is more virulent than other enteric bacteria. For example, studies reported by Fairley et al. On bladder and kidney mapping have shown that virtually all Proteus patients with urinary tract disease have evidence of upper urinary tract infection. Studies in animal models by Musher et al. And Aronson et al. Showed that the virulence of Proteus infection was greatly diminished when ammonia production was inhibited. In this case, Proteus behaves exactly like other gut bacteria. The above studies indicate the potential importance of urease as a virulence factor for Proteus. The exact mechanism is unclear. Another problem with Proteus infection is most resistance